Loading…
Vyome Holdings Inc Is A Clinical-Stage Specialty Pharmaceutical Company Working To Treat Immune-Inflammatory And Rare Diseases Of Unmet Need With Next-Generation Therapeutic Solutions. Its Product Candidates Are: Vt-1953, A Topical Gel That Is Being Developed To Treat Signs And Symptoms Of Malignant Fungating Wounds In Cancer; Vt-1908, A Repurposed Immune Modulator To Treat Steroid-Sparing Anterior Uveitis; And Vb1953, Which Is Being Developed To Treat Moderate To Severe Acne. Vyome Has Also Commercialized Two Novel Reformulated Topical Anti-Fungal Products Based On The Technology Platform Of Molecular Replacement Therapeutics (Mrt) In India: A Dandruff Lotion And Shampoo. It Operates In Two Segments: Pharmaceutical Products, Which Generate The Maximum Revenue, And Biotechnology.